Primary Sclerosing Cholangitis (PSC) Market Snapshot (2023 to 2033)
The global Primary Sclerosing Cholangitis (PSC) market size is expected to be valued at US$ 151.07 Million in 2023. With the increasing alcohol consumption among people, the overall demand for Primary Sclerosing Cholangitis (PSC)is projected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033.
Data Points
Key Statistics
Primary Sclerosing Cholangitis (PSC) Market Value 2023
US$ 151.07 Million
Primary Sclerosing Cholangitis (PSC) Market Projected Value (2033)
US$ 314.26 Million
Primary Sclerosing Cholangitis (PSC) Market CAGR (2023 to 2033)
7.6%
According to the analysis of Future Market Insights, the Primary Sclerosing Cholangitis (PSC) market is expected to fuel over the analysis period, attributed to the factors such as the rise in the incidences of liver diseases, as well as the rise in alcohol consumption. As per the Centers for Disease Control and Prevention, the global incidence of liver disease was 3.9 million in 2016. As per the World Health Organization (WHO), the prevalence of liver cirrhosis is increasing in European countries, due to the high consumption of alcohol. Furthermore, rising awareness programs and an upsurge in Research and Development investment for the development of new drug molecules are other factors that are expected to augment the growth of the primary sclerosing cholangitis market during the forecast period.
The rising frequency of disorders linked to PSC, such as liver cancer and inflammatory bowel disease, is another factor that is anticipated to fuel the therapeutic acceptance of effective pharmaceuticals to treat the condition, which in turn is expected to accelerate the market growth. As per the World Journal of Gastroenterology, Inflammatory bowel disease (IBD) is detected in 50-80 percent of patients with PSC, with ulcerative colitis (UC) accounting for 80-90 percent of these instances.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Primary Sclerosing Cholangitis (PSC) Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Primary Sclerosing Cholangitis (PSC) is projected to increase at a CAGR of 7.6% during the forecast period between 2023 and 2033, reaching a total of US$ 314.26 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.8%.
According to Future Market Insights, a market research and competitive intelligence provider, the Primary Sclerosing Cholangitis (PSC) market was valued at US$ 140.4 Million in 2022.
As per the report of NCBI, in 2018, there were approximately 0.2-1.2 million people having primary sclerosing cholangitis, in Northern European countries and North America, where the disease is most common, and almost more than half of these cases could have been avoided with the availability of proper medical treatment.
Thus, factors such as a rise in the number of cholangitis cases and an increase in product approvals by several regulatory authorities globally are projected to fuel the revenue share of the market in the forthcoming years. Hence, increasing prevalence, as well as incidence rates of liver failure, and bile cancer associated with cholangitis, is one of the major factors that are likely to escalate the demand for PSC over the forecast period.
Which Drivers underpin Primary Sclerosing Cholangitis (PSC) Industry Expansion?
Affordable Treatment Optionsto Fuel the Market Growth
Currently, a liver transplant is one of the major causes of liver transplantation in the USA and is the only known cure for primary sclerosing cholangitis. However, according to a February 2018 survey by Mayo Clinic, the disease is projected to recur in the transplanted liver in 27.2% of the patients, thereby demanding efficient as well as affordable therapeutic solutions to cater to unmet patient needs. As per the United Network for Organ Sharing (UNOS), 2018, the estimated bill charges for a liver transplant procedure are around US$ 577,100 in the USA.
Additionally, there are major risk factors associated with liver transplantation that causes the death of the patient. For instance, in May 2019, as per the data published by the National Center for Biotechnology Information, pre-transplant malignancies were identified as those malignancies known prior to the transplant and those found only on pathologic evaluation of the explant. In addition, as per the data published by Mayo Clinic in March 2022, about 75% of people who undergo liver transplants live for at least five years. This means that for every 100 people who receive a liver transplant for any reason, about 75 will live for five years and 25 will die within five years.
Hence, the requirement of providing affordable treatment, due to increasing risk factors resulting in the development of serious disorders, and high costs associated with liver transplantation are major factors that are anticipated to fuel the adoption of primary sclerosing cholangitis drugs, which in turn are likely to boost the market growth over the analysis period.
Rise in Prevalence of Liver Failure & Bile Cancer to Accelerate the Market Growth
The rising incidence of diseases associated with primary sclerosing cholangitis, including liver cancer and inflammatory bowel disease, is expected to boost the therapeutic adoption of efficient drugs to manage the condition, thus accelerating the growth of the primary sclerosing cholangitis market.
For instance, in May 2021, as per an article published by Springer Nature Limited, a diagnosis of primary sclerosing cholangitis (PSC) has been associated with the increased risk of colorectal cancer, hepatobiliary cancers, and all-cause mortality in several studies, while associations with cardiovascular disease have been inconsistent. In addition, an incidence of 0.4-0.7 cases per 100,000 in the UK, and a prevalence of 3.9-16.2 per 100,000 of liver failure were reported.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Primary Sclerosing Cholangitis (PSC) Market?
Stringent Government Regulations to Restrain the Market Growth
The withdrawal of novel molecules from late-stage clinical trials, coupled with stringent regulations for the approval of the drugs are the major factors that are anticipated to hamper the market growth in the coming years. For instance, approval of Ursodeoxycholic acid (UDCA) by the US Food and Drug Administration (FDA) for the treatment of Primary Biliary Cholangitis (PBC) required overcoming several barriers to drug development, and these barriers continue to pose challenges for current as well as the future drug development.
As cholangitis is a rare disease, the recruitment of adequate numbers of PBC patients to power clinical trials requires many participating sites. Moreover, clinical outcomes, including liver transplantation and survival, occur at a low rate, particularly in patients with early-stage disease. Hence, the timeframe for a clinical trial to demonstrate clinical benefits is not practical, especially for therapies that may be most effective in early-stage disease. Thus, these challenges are projected to limit the market growth in the near future.
High Cost of Drug Development to Limit the Market Growth
The high cost associated with drug development is one of the major factors that is anticipated to restrain the growth of the primary sclerosing cholangitis market during the forecast period. In addition, the withdrawal of molecules from late clinical stages is another factor that will hinder market growth.
Factors such as development activities in this direction, as well as a lack of initiatives by the government to spread awareness and undertake research, will further impede market growth in the near future. Also, the lack of skilled professionals or trained expertise in this area in low-and-middle class economies will further hamper in the way of growth over the analysis period.
Region-wise Insights
Will North America Continue Dominance in the Global Primary Sclerosing Cholangitis (PSC) Market?
Increase in R&D Proficiencies in the Region to Fuel the Market Growth
The Primary Sclerosing Cholangitis (PSC) Market in North America is expected to accumulate the highest market share of 42% in 2023.
Factors such as higher healthcare spending as well as favorable reimbursement scenario are expected to fuel the regional market growth during the forecast period. In addition, a developed regulatory framework, and a rise in awareness about new treatment options are other factors driving the market growth in the region.
Other factors including the rise in the research and development proficiencies by the pharmaceutical companies, rapid adoption of new and better healthcare technologies, and prevalence of sophisticated healthcare infrastructure are also likely to stimulate the demand for primary sclerosing cholangitis drugs, which in turn will boost the revenue share of the market. Favorable reimbursement policies are also inducing the dominance of the region.
North America dominated the global primary sclerosing cholangitis market in terms of revenue share in 2019. The region is expected to continue its dominance over the forecast period. This can be attributed to a rise in awareness about PSC, the availability of effective treatment methods, and the presence of well-established healthcare facilities. In addition, the increasing prevalence of diabetes and hypertension is also anticipated to drive regional growth during the forecast period.
In 2016, there were an estimated 83,081 people living with liver and intrahepatic bile duct cancer in the USA. Thus, rising bile duct cancer is another factor that is boosting the market growth in the region. The region is expected to hold the highest CAGR of 7.5% during the forecast period.
How Will the Growth of the Primary Sclerosing Cholangitis (PSC) Market unfold in Asia Pacific?
Growing Medical Tourism Industry in the Region to Fuel the Market Growth
The Primary Sclerosing Cholangitis (PSC) Market in Asia Pacific is expected to accumulate the highest market share of 40% in 2023.
Enhanced healthcare infrastructure and reimbursement policies across emerging economies including India and China, coupled with increasing incidence rates associated with PSC are the major factors that are driving the market growth in Asia Pacific.
In addition, the surging medical tourism industry, due to its low-cost burden, and enhanced healthcare services are the other key factors that are projected to contribute to regional market demand over the analysis period. Additionally, the market is expected to be driven by factors such as rising incidences of liver diseases and disorders. The region is expected to hold the highest CAGR of 7.4% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Type, which Primary Sclerosing Cholangitis (PSC) Category will remain prominent?
Primary Sclerosing Cholangitis Segment to beat Competition in Untiring Market
On the basis of type, the global Primary Sclerosing Cholangitis (PSC) market is dominated by the Primary Sclerosing Cholangitis Segment, which accounts for a share of 45%. The segment is expected to hold a CAGR of 7.5% over the analysis period.
The segment’s growth is attributed to the factors such as the growing research & development activities for the treatment. Primary sclerosing cholangitis is a progressive, rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the bile ducts. Both intra- and extra-hepatic bile ducts are affected. This generally leads to cholestasis, liver cirrhosis, and eventually liver failure.
By Application, which Primary Sclerosing Cholangitis (PSC) Category dominates?
Hospitals Segment to Drive the Primary Sclerosing Cholangitis (PSC) Market
Based on the Application, the hospital's segment is expected to witness a significant growth of 62% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 7.4% CAGR over the analysis period.
This growth is attributed to rising incidence rates of MPSC among hospitalized patients across the globe. Hospital-based clinics have been found most effective in diagnosing and treating primary sclerosing cholangitis due to their access to advanced healthcare facilities, along with experienced medical professionals, which has led them to be considered one of the best treatment centers for this disease.
The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?
Primary Sclerosing Cholangitis (PSC) Market start-up players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Founded in 2014, PBC is a provider of an application for monitoring primary biliary cholangitis (PBC). The company offers an app for tracking and monitoring all aspects of primary biliary cholangitis (PBC). Its features include tracking Liver markers to input alkaline phosphatase (ALP) and bilirubin levels.
Hepagene, a start-up established in 2016, is a developer of therapeutics for liver diseases and other life-threatening diseases. The products pipeline includes HPG1860 for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (IND completed), primary sclerosing cholangitis (IND), HPG2746 for NASH, HPG2466 for Hepatitis B infection (HBV), and HPG4980 for Hepatocellular Carcinoma (HCC).
Started in 2015, Qing Bile Therapeutics is a developer of bile acid-based therapeutics to treat liver diseases. The company has identified and developed tetrahydroxylated bile acids (THBAs) to treat cholestatic and metabolic diseases. Moreover, the company identified the bile acid in Bsep -/- mice (a model of human progressive familial intrahepatic cholestasis type II (PFIC2)) having normal levels of liver indicators and normal hepatocyte morphology even in the diseased condition due to high levels of TBHA.
Who are the Leading Players in the Primary Sclerosing Cholangitis (PSC) Market?
Prominent players in the Primary Sclerosing Cholangitis (PSC) market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd., among others.
Recent Developments:
In April 2022, Sirnaomics, a clinical-stage RNA therapeutics biopharmaceutical company, carried out a Phase I clinical trial analyzing the potential of STP707 to treat liver fibrosis in primary sclerosing cholangitis in the USA A systemic small interfering ribonucleic acid (siRNA) therapy STP707 comprises two siRNA oligonucleotides that act on TGF-β1 and COX-2 mRNA, respectively.
In February 2022, Siranomics received the safe-to-proceed approval letter from the US Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application forSTP707, it's lead siRNA (small interfering RNA) drug candidate in Primary Sclerosing Cholangitis. The Company anticipates initiating a Phase I study in the second quarter of 2022, to evaluate the safety, tolerability, and pharmacokinetics of STP707, administered intravenously in healthy volunteers.
In January 2022, Engitix built a Liver Disease Pipeline with €48M Series A round and a drug discovery partnership with the Milan-based Dompé Farmaceutici. The proceeds from Engitix’s Series A round will bankroll the development of the company’s tissue models for use in drug discovery. Moreover, the investment will fuel the preclinical development of Engitix’s drug pipeline, with a focus on treating liver diseases including primary sclerosing cholangitis and liver cancer. The first candidate is expected to reach phase I testing by 2025.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 7.6% from 2023 to 2033
Market Value in 2023
US$ 151.07 Million
Market Value in 2033
US$ 314.26 Million
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug
Region
Regions Covered
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Key Segments Covered in the Primary Sclerosing Cholangitis (PSC) Industry Analysis
Primary Sclerosing Cholangitis (PSC) Market by Drug:
BTT1023
GS-9674
NGM282
OCA
Cenicriviroc
LUM001
DUR928
norUDCA
HTD1801
IDN-7314
STP705
Primary Sclerosing Cholangitis (PSC) Market by Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Frequently Asked Questions
What was the market value for Primary Sclerosing Cholangitis (PSC) in 2022?
As of 2022, the market for Primary Sclerosing Cholangitis (PSC) was valued at US$ 140.4 Million, as per FMI.
At what value did the Primary Sclerosing Cholangitis (PSC) Market close in 2023?
By 2023-end, sales of Primary Sclerosing Cholangitis (PSC) closed at a value of US$ 151.07 Million.
What was the last 4 years value CAGR for Primary Sclerosing Cholangitis (PSC)?
From 2018 to 2022, Primary Sclerosing Cholangitis (PSC) demand expanded at a CAGR of 2.8%
What is the projected forecast CAGR for the Primary Sclerosing Cholangitis (PSC) Industry from 2023 to 2033?
From 2023 to 2033, Primary Sclerosing Cholangitis (PSC) sales are expected to flourish at a CAGR of 7.6%
According to FMI, what is the anticipated market value for Primary Sclerosing Cholangitis (PSC) in 2033?
By 2033, the market value of Primary Sclerosing Cholangitis (PSC) is expected to reach US$ 314.26 Million.
By Type, which category ranks first with regard to Primary Sclerosing Cholangitis (PSC)?
By Type, the Primary Sclerosing Cholangitis segment constitutes the bulk of market share of 45% in 2022.
By Application, which category ranks first with regard to Primary Sclerosing Cholangitis (PSC)?
By Application, the Hospitals segment dominates the market with a share of 62% in 2022.
Table of Content
1. Executive Summary | Primary Sclerosing Cholangitis (PSC) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
5.3.1. BTT1023
5.3.2. GS-9674
5.3.3. NGM282
5.3.4. OCA
5.3.5. Cenicriviroc
5.3.6. LUM001
5.3.7. DUR928
5.3.8. norUDCA
5.3.9. HTD1801
5.3.10. IDN-7314
5.3.11. STP705
5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
7.2.1. By Country
7.2.1.1. United States of America
7.2.1.2. Canada
7.2.2. By Drug
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Drug
7.4. Key Takeaways
8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Drug
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug
8.4. Key Takeaways
9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. United Kingdom
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Russia
9.2.1.7. Rest of Europe
9.2.2. By Drug
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug
9.4. Key Takeaways
10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. India
10.2.1.4. South Korea
10.2.1.5. Australia
10.2.1.6. Rest of APAC
10.2.2. By Drug
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug
10.4. Key Takeaways
11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. South Africa
11.2.1.2. Saudi Arabia
11.2.1.3. UAE
11.2.1.4. Israel
11.2.1.5. Rest of MEA
11.2.2. By Drug
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug
11.4. Key Takeaways
12. Key Countries Market Analysis
12.1. United States of America
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2022
12.1.2.1. By Drug
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2022
12.2.2.1. By Drug
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2022
12.3.2.1. By Drug
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2022
12.4.2.1. By Drug
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2022
12.5.2.1. By Drug
12.6. United Kingdom
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2022
12.6.2.1. By Drug
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2022
12.7.2.1. By Drug
12.8. Spain
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2022
12.8.2.1. By Drug
12.9. Italy
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2022
12.9.2.1. By Drug
12.10. Russia
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2022
12.10.2.1. By Drug
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2022
12.11.2.1. By Drug
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2022
12.12.2.1. By Drug
12.13. India
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2022
12.13.2.1. By Drug
12.14. South Korea
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2022
12.14.2.1. By Drug
12.15. Australia
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2022
12.15.2.1. By Drug
12.16. South Africa
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2022
12.16.2.1. By Drug
12.17. Saudi Arabia
12.17.1. Pricing Analysis
12.17.2. Market Share Analysis, 2022
12.17.2.1. By Drug
12.18. UAE
12.18.1. Pricing Analysis
12.18.2. Market Share Analysis, 2022
12.18.2.1. By Drug
12.19. Israel
12.19.1. Pricing Analysis
12.19.2. Market Share Analysis, 2022
12.19.2.1. By Drug
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Drug
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. Acorda Therapeutics, Inc.
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. Gilead Sciences, Inc.
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. NGM Biopharmaceuticals, Inc.
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. Intercept Pharmaceuticals, Inc.
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Falk Pharma GmbH
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Allergan Plc.
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. Takeda Pharmaceutical Company
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. Durect Corporation
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. Conatus Pharmaceuticals, Inc.
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Sirnaomics, Inc.
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
15. Assumptions & Acronyms Used16. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 3: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 5: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 7: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 9: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Asia Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 11: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Middle East and Africa Market Value (US$ Million) Forecast by Drug, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 3: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 9: Global Market Attractiveness by Drug, 2023 to 2033
Figure 10: Global Market Attractiveness by Region, 2023 to 2033
Figure 11: North America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 12: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 13: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 16: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 17: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 18: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 19: North America Market Attractiveness by Drug, 2023 to 2033
Figure 20: North America Market Attractiveness by Country, 2023 to 2033
Figure 21: Latin America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 22: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 23: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 26: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 27: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 29: Latin America Market Attractiveness by Drug, 2023 to 2033
Figure 30: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 31: Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 32: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 33: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 34: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 35: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 36: Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 37: Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 38: Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 39: Europe Market Attractiveness by Drug, 2023 to 2033
Figure 40: Europe Market Attractiveness by Country, 2023 to 2033
Figure 41: Asia Pacific Market Value (US$ Million) by Drug, 2023 to 2033
Figure 42: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 43: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 44: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 45: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 46: Asia Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 47: Asia Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 48: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 49: Asia Pacific Market Attractiveness by Drug, 2023 to 2033
Figure 50: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 51: Middle East and Africa Market Value (US$ Million) by Drug, 2023 to 2033
Figure 52: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 53: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 54: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 55: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 56: Middle East and Africa Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 57: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 58: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 59: Middle East and Africa Market Attractiveness by Drug, 2023 to 2033
Figure 60: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
